finasteride has been researched along with Adenocarcinoma in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 19 (61.29) | 29.6817 |
| 2010's | 5 (16.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cagnon, VH; Hetzl, AC; Kido, LA; Montico, F | 1 |
| Kim, J; Li, J | 1 |
| Bruchovsky, N; Locke, JA | 1 |
| Türkeri, L | 1 |
| Ahles, T; Gu, L; Halabi, S; Hussain, A; Kaplan, E; Kelly, WK; Monk, JP; Philips, G; Picus, J; Small, EJ; Vogelzang, N | 1 |
| Damjanoski, I; Küfer, R; Müller, J; Rinnab, L; Schnöller, TJ | 1 |
| Bahnson, R; Bissonette, EA; Miller, NL; Theodorescu, D; Wilson, J | 1 |
| Bittmann, L; Brufsky, A; Kantoff, PW; Kaplan, ID; Kaufman, DS; Manola, J; Oh, WK; Smith, MR | 1 |
| Barqawi, AB; Crawford, ED; Handel, L; Moul, JW; Ziada, A | 1 |
| Hellerstedt, B | 1 |
| Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C | 1 |
| Bostwick, DG; Civantos, F; Montironi, R; Qian, J; Roehrborn, CG | 1 |
| Febbo, PG; George, DJ; Kantoff, PW; Kaplan, ID; Kaufman, DS; Leibowitz, SB; Manola, J; Oh, WK; Regan, MM; Smith, MR; Tay, MH | 1 |
| Levinson, A; Lowe, FC; Nagler, EA | 1 |
| Bissonette, E; Miller, N; Smolkin, ME; Theodorescu, D | 1 |
| Goodman, PJ; Klein, EA; Lippman, SM; Tangen, CM; Thompson, IM | 1 |
| Talcott, JA | 1 |
| Carroll, PR; Cowan, JE; DuChane, J; Elkin, EP; Kawakami, J; Latini, DM | 1 |
| Albanes, D; Chi, C; Gong, Z; Goodman, PJ; Hsing, AW; Kristal, AR; Lippman, SM; Neuhouser, ML; Platz, EA; Pollak, MN; Thompson, IM | 1 |
| Asamoto, M; Cho, YM; Shirai, T; Suzuki, S; Takahashi, S; Tang, M | 1 |
| Audia, JE; Bruchovsky, N; Goode, RL; Hsiao, KC; Kaefer, M; Krushinski, JH; Lee, C; Leibovitch, IY; Neubauer, BL; Steidle, CP; Sutkowski, DM | 1 |
| di Salle, E; Giudici, D; Zaccheo, T | 1 |
| Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P | 1 |
| Akaza, H; Ideyama, Y; Onozawa, M; Shirai, T; Tsukamoto, S | 1 |
| Cote, RJ; Henderson, BE; Mertes, SJ; Pike, MC; Ross, RK; Salem, CE; Skinner, EC; Stanczyk, FZ | 1 |
| Bostwick, DG | 1 |
| Bostwick, DG; Cheng, L; Ramnani, D | 1 |
| Leibowitz, RL; Tucker, SJ | 1 |
| Brooks, JD; DePrimo, SE; Shinghal, R; Vidanes, G | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Barnes, S; Brawley, OW; Parnes, H | 1 |
8 review(s) available for finasteride and Adenocarcinoma
| Article | Year |
|---|---|
Molecular profiles of finasteride effects on prostate carcinogenesis.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgens; Animals; Anticarcinogenic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azasteroids; Dihydrotestosterone; Disease Progression; Dutasteride; Epithelial Cells; Finasteride; Humans; Isoenzymes; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Patient Selection; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Stromal Cells | 2009 |
Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Tosyl Compounds; Treatment Outcome | 2003 |
Does finasteride alter the pathology of the prostate and cancer grading?
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Animals; Disease Models, Animal; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms | 2004 |
Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.
Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Agents, Hormonal; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Brachytherapy; Case Management; Combined Modality Therapy; Cryosurgery; Finasteride; Follow-Up Studies; HIV Infections; Humans; Leuprolide; Life Expectancy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, High-Energy; Retrospective Studies; Tosyl Compounds | 2005 |
Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation.
Topics: Adenocarcinoma; Androgen Antagonists; Cholestenone 5 alpha-Reductase; Diagnosis, Differential; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Male; Oxidoreductases; Prostatic Neoplasms | 1998 |
Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Male; Prostatic Hyperplasia; Prostatic Neoplasms | 1999 |
Prevention of prostate cancer.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Anticarcinogenic Agents; Antioxidants; Carotenoids; Case-Control Studies; Cohort Studies; Dietary Fats; Double-Blind Method; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Incidence; Insulin-Like Growth Factor I; Life Style; Lycopene; Male; Mice; Mice, Transgenic; Micronutrients; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Racial Groups; Randomized Controlled Trials as Topic; Risk Factors; Selenium; Soybean Proteins; Vitamin D; Vitamin E | 2001 |
The future of prostate cancer prevention.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Anticarcinogenic Agents; Antioxidants; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diet; Double-Blind Method; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Selenium; Soybean Proteins; Treatment Outcome; Vitamin A; Vitamin D; Vitamin E | 2001 |
8 trial(s) available for finasteride and Adenocarcinoma
| Article | Year |
|---|---|
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Failure | 2012 |
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Finasteride; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Flutamide; Follow-Up Studies; Humans; Life Tables; Male; Neoplasm Recurrence, Local; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Radioisotope Teletherapy; Survival Analysis; Treatment Outcome | 2003 |
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
Topics: Adenocarcinoma; Age Factors; Aged; Body Mass Index; Diabetes Mellitus; Enzyme Inhibitors; Finasteride; Humans; Logistic Models; Male; Middle Aged; Neoplasm Staging; Obesity; Prostatic Neoplasms; Research Design; Risk Factors; Waist-Hip Ratio | 2006 |
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Sexuality; Treatment Failure | 1997 |
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
Topics: Adenocarcinoma; Aged; Biopsy; Cell Division; Enzyme Inhibitors; Epithelial Cells; Evaluation Studies as Topic; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms | 1998 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
15 other study(ies) available for finasteride and Adenocarcinoma
| Article | Year |
|---|---|
Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Angiogenesis Inhibitors; Animals; Blotting, Western; Cyclohexanes; Disease Models, Animal; Endostatins; Fibroblast Growth Factor 2; Finasteride; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Pyrroles; Sesquiterpenes; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Time Factors | 2010 |
Editorial comment.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2010 |
[Histopathology reports of findings of prostate needle biopsies. Individual treatment].
Topics: Adenocarcinoma; Attitude of Health Personnel; Biomarkers, Tumor; Biopsy, Needle; Cell Proliferation; Cooperative Behavior; Decision Support Techniques; Disease Progression; Finasteride; Germany; Guideline Adherence; Humans; Interdisciplinary Communication; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Palliative Care; Patient Care Planning; Phosphodiesterase 5 Inhibitors; Precision Medicine; Prognosis; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Surveys and Questionnaires | 2013 |
Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Brachytherapy; Chemotherapy, Adjuvant; Diarrhea; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Logistic Models; Male; Nitriles; Penile Erection; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome; Urinary Incontinence | 2003 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietary Supplements; Doxazosin; Drug Utilization; Family; Finasteride; Health Surveys; Humans; Male; Mass Screening; Middle Aged; Penile Erection; Phytotherapy; Plant Preparations; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Self Medication; Socioeconomic Factors; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders; Vitamins | 2004 |
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds | 2004 |
Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Humans; Leuprolide; Male; Neoadjuvant Therapy; Neoplasm Staging; Palladium; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Survival Rate; Testosterone; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
Topics: Adenocarcinoma; Biopsy, Needle; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Odds Ratio; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2005 |
Rebalancing ratios and improving impressions: later thoughts from the prostate cancer prevention trial investigators.
Topics: Adenocarcinoma; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2005 |
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Survival Rate | 2006 |
Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Animals, Genetically Modified; Antigens, Viral, Tumor; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide; Male; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Testosterone | 2007 |
Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstadienes; Benzoquinones; Cell Division; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Male; Prostatic Neoplasms; RNA, Messenger; Selection, Genetic; Skin; Testosterone; Tumor Cells, Cultured | 1996 |
Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Leuprolide; Luteinizing Hormone; Male; Organ Size; Pituitary Gland, Anterior; Prostate; Prostatic Neoplasms; Random Allocation; Rats; Seminal Vesicles; Testis; Testosterone | 1997 |
A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adenocarcinoma; Aminobiphenyl Compounds; Androgen Antagonists; Anilides; Animals; Carcinogens; Disease Progression; Enzyme Inhibitors; Finasteride; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Testosterone; Tosyl Compounds | 1998 |